Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma
CONCLUSIONS: Outside of clinical trials, immunotherapy for resectable esophageal carcinoma is limited to the adjuvant setting. Phase III trials investigating neoadjuvant and perioperative immunotherapy are now underway and will provide much-needed data on survival that may ultimately lead to practice-changing recommendations.PMID:38408631 | DOI:10.1016/j.athoracsur.2024.02.021
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Cameron N Fick Elizabeth G Dunne Smita Sihag Daniela Molena Samuel L Cytryn Yelena Y Janjigian Abraham J Wu Stephanie G Worrell Wayne L Hofstetter David R Jones Katherine D Gray Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Databases & Libraries | Esophagus Cancer | Gastroenterology | Gastroschisis Repair | History of Medicine | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Skin Cancer | Squamous Cell Carcinoma | Study